HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?

Most of the health care sector's headlines are dominated by Big Pharma giants. Legacy companies, including AbbVie (NYSE: ABBV), Eli Lilly (NYSE: LLY), Pfizer (NYSE: PFE), and Merck (NYSE: MRK)—and their lineup of game-changing drugs—receive the lion’s share of attention. But one newcomer is making a splash, and investors looking for growth opportunities in the health space should be paying attention. 

Founded in November 2017, Hims & Hers Health (NYSE: HIMS) went public in January 2021. By the end of 2024, the consumer-focused health platform was able to post its first year of profitability, with net income of $126 million. 

While that figure pales in comparison to mega-cap giants like Pfizer, it demonstrates a level of discipline rarely seen among companies that are less than five years removed from their IPOs. That, combined with operations at the confluence of several high-demand industries, makes Hims & Hers Health an intriguing buy-and-hold prospect.  

A Turbulent Year for Shareholders 

Fundamentally, the young company’s debt management has been exemplary. That has been accentuated by a nearly 244% increase in net cash from operating activities from 2023 to 2024. 

When Hims & Hers Health reported Q3 financials on Nov. 3, it missed on earnings by just 3 cents and beat on revenue, with $598.98 million representing a 49.2% year-over-year increase.

In his comments, CEO and cofounder Andrew Dudum highlighted that “At the end of the quarter, subscribers using personalized solutions grew 50% year-over-year, helping drive nearly 50% in year-over-year revenue growth.” 

Most notably, the company’s debt-to-equity ratio of 1.67 and its forward price-to-earnings (P/E) ratio of 52.79—a marked improvement of its trailing 12-month P/E of 67.33—suggests that earnings next year should grow by more than 79% from 29 cents per share to 52 cents per share. 

Since 2021, Hims & Hers Health has averaged annual earnings before interest, taxes, depreciation, and amortization (EBITDA) growth of 37.14%, revenue growth of 77.85%, and earnings per share (EPS) growth of 169.63%.

Despite these robust fundamentals, 2025 required a strong stomach for shareholders in HIMS. The stock’s performance has been nothing short of a roller coaster ride this year, featuring both meteoric rises and dramatic crashes in rapid succession. 

From Jan 2. to Feb. 19, HIMS gained nearly 173% before giving more than 63% back by April 22. By May 19, it had gained nearly 146% before plunging 36% lower by June 25. At the end of July, it had regained 60%, and at the time of writing, the stock is down another 45% from that high.

HIMS Is at the Center of Multiple High-Growth Industries 

Still, since going public, the stock is up almost 139%. Hims & Hers Health has shown exceptionally strong growth while its management has produced balance sheets that are nothing short of admirable. The company’s accessible, direct-to-consumer telehealth model has positioned it at the intersection of multiple high-growth industries.

According to market consultancy firm Grand View Research, the sexual health supplement market is projected to enjoy a compound annual growth rate (CAGR) of 10.4% from 2024 through 2030.

The hair thinning market’s projected CAGR during the same period is 10.85%, while the telehealth market is expected to grow by a CAGR of 24.68%. 

Perhaps most notably, Hims & Hers Health also offers compounded GLP-1 injections, which contain the same ingredients as Novo Nordisk’s (NYSE: NVO) Ozempic and Wegovy. The GLP-1 weight loss market during that forecast period is projected to be 18.54%. 

Additionally, Dudum noted in the company’s Q3 earnings call that Hims & Hers Health is in ongoing discussions with Novo Nordisk to distribute both injection and oral formulations of Wegovy on the Hims & Hers platform, pending FDA approval.

Here’s What Wall Street Thinks of HIMS

Ten of the 15 analysts covering Hims & Hers Health rate it a Hold, and the stock carries a consensus Reduce rating. Still, 15 analysts’ average 12-month price target is $45.27, which suggests potential upside performance of 24.51%. 

However, the current level of short interest may give prospective investors pause. That stands at a significant 37.54% of the company’s float. But for those who are considering HIMS as a long-term investment, institutional ownership—which remains strong at nearly 64%—provides a vote of confidence.

Underscoring the smart money’s bullish stance on Hims & Hers Health, over the past 12 months, 425 institutional buyers have injected $2.31 billion in inflows, compared to just 194 institutional sellers pulling out $1.17 billion.

Where Should You Invest $1,000 Right Now?

Before you make your next trade, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.

Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.

They believe these five stocks are the five best companies for investors to buy now...

See The Five Stocks Here

The article "HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?" first appeared on MarketBeat.